Paxman AB (publ) (STO:PAX)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.49B -5.5% |
| Revenue (ttm) | 365.91M +34.1% |
| Net Income | -5.64M |
| EPS | -0.27 |
| Shares Out | 23.27M |
| PE Ratio | n/a |
| Forward PE | 19.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35 |
| Open | 63.00 |
| Previous Close | 64.40 |
| Day's Range | 63.00 - 63.90 |
| 52-Week Range | 41.00 - 70.20 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 20, 2026 |
About Paxman AB
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden. [Read more]
Financial Performance
Financial StatementsNews
Paxman AB Earnings Call Transcript: Q2 2026
Group sales grew 40% year-over-year, driven by strong U.S. insurance-based billing and a record SEK 105 million in revenue. EBITDA margin improved, and the neuropathy device's U.S. launch is delayed to Q2 2027 due to an FDA De Novo pathway.
Paxman AB Quarterly report: Q2 2026
Paxman AB has published its Q2 2026 quarterly earnings report on August 21, 2026.
Paxman AB Earnings Call Transcript: Q1 2026
Group sales hit a record SEK 90 million in Q1, up over 30% year-over-year, with EBITDA at SEK 10.5 million and strong cash reserves. U.S. insurance-based billing and state legislation are driving momentum, while CIPN investments and Dignitana integration continue to support growth.
Paxman AB Quarterly report: Q1 2026
Paxman AB has published its Q1 2026 quarterly earnings report on May 21, 2026.
Paxman AB Transcript: DNB Carnegie Healthcare Seminar 2026
Significant growth in 2025 was driven by a major acquisition, record sales, and a strategic shift to insurance-based billing in the US. Regulatory progress and new product launches are set to accelerate growth, with a focus on operational excellence and expanding standard of care globally.
Paxman AB Earnings Call Transcript: Q4 2025
Q4 saw strong sales growth driven by the Dignitana acquisition and robust U.S. insurance-based billing, with group net sales up to SEK 84 million. Strategic focus is on U.S. expansion, new product launches, and leveraging CPT I codes for improved reimbursement.
Paxman AB Quarterly report: Q4 2025
Paxman AB has published its Q4 2025 quarterly earnings report on February 27, 2026.
Paxman AB Annual report: Q4 2025
Paxman AB has published its Q4 2025 annual report on February 27, 2026.
Paxman AB Transcript: DNB Carnegie Småbolagsdag
The company is rapidly expanding in medtech, focusing on cryotherapy for chemotherapy side effects and transitioning to an insurance-based billing model to drive U.S. growth. Key priorities include integrating a major competitor, launching new products, and leveraging legislative changes for broader insurance coverage by 2026.
Paxman AB Transcript: CMD 2025
Expansion into CIPN and side effect management is underway, with U.S. commercialization and reimbursement strategies prioritized. Regulatory submissions for the new device are on track, and integration of Dignitana strengthens market reach and profitability. High demand, improved coverage, and operational efficiencies are expected to drive growth.
Paxman AB Earnings Call Transcript: Q3 2025
Record Q3 revenue driven by Dignitana integration and strong US focus, with EBITDA margin at 9%. CIPN commercialization and insurance-based billing remain key growth drivers, while legislative and regulatory developments support future expansion.
Paxman AB Quarterly report: Q3 2025
Paxman AB has published its Q3 2025 quarterly earnings report on November 14, 2025.